| Denosumab for prevention of fractures in postmenopausal women with osteoporosis SR Cummings, JS Martin, MR McClung, ES Siris, R Eastell, IR Reid, ... New England Journal of Medicine 361 (8), 756-765, 2009 | 4013 | 2009 |
| Romosozumab treatment in postmenopausal women with osteoporosis F Cosman, DB Crittenden, JD Adachi, N Binkley, E Czerwinski, S Ferrari, ... New England Journal of Medicine 375 (16), 1532-1543, 2016 | 1446 | 2016 |
| Romosozumab in postmenopausal women with low bone mineral density MR McClung, A Grauer, S Boonen, MA Bolognese, JP Brown, ... New England Journal of Medicine 370 (5), 412-420, 2014 | 1238 | 2014 |
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 … JP Brown, RL Prince, C Deal, RR Recker, DP Kiel, LH De Gregorio, ... Journal of bone and mineral research 24 (1), 153-161, 2009 | 791 | 2009 |
| Vertebral bone density in children: effect of puberty. V Gilsanz, DT Gibbens, TF Roe, M Carlson, MO Senac, MI Boechat, ... Radiology 166 (3), 847-850, 1988 | 495 | 1988 |
| Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men A Menkes, S Mazel, RA Redmond, K Koffler, CR Libanati, CM Gundberg, ... Journal of applied physiology 74 (5), 2478-2484, 1993 | 464 | 1993 |
| Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension S Papapoulos, R Chapurlat, C Libanati, ML Brandi, JP Brown, ... Journal of Bone and Mineral Research 27 (3), 694-701, 2012 | 457 | 2012 |
| Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open … BL Langdahl, C Libanati, DB Crittenden, MA Bolognese, JP Brown, ... The Lancet 390 (10102), 1585-1594, 2017 | 392 | 2017 |
| Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate E Seeman, PD Delmas, DA Hanley, D Sellmeyer, AM Cheung, E Shane, ... Journal of Bone and Mineral Research 25 (8), 1886-1894, 2010 | 346 | 2010 |
| The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study S Papapoulos, K Lippuner, C Roux, CJF Lin, DL Kendler, EM Lewiecki, ... Osteoporosis international 26, 2773-2783, 2015 | 320 | 2015 |
| Effects of denosumab on bone turnover markers in postmenopausal osteoporosis R Eastell, C Christiansen, A Grauer, S Kutilek, C Libanati, MR McClung, ... Journal of Bone and Mineral Research 26 (3), 530-537, 2011 | 255 | 2011 |
| Effects of strength training on bone mineral density: hormonal and bone turnover relationships AS Ryan, MS Treuth, MA Rubin, JP Miller, BJ Nicklas, DM Landis, ... Journal of applied physiology 77 (4), 1678-1684, 1994 | 205 | 1994 |
| Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences B Ettinger, S Sidney, SR Cummings, C Libanati, DD Bikle, IS Tekawa, ... The Journal of Clinical Endocrinology & Metabolism 82 (2), 429-434, 1997 | 201 | 1997 |
| Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures M Austin, YC Yang, E Vittinghoff, S Adami, S Boonen, DC Bauer, ... Journal of Bone and Mineral Research 27 (3), 687-693, 2012 | 183 | 2012 |
| National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges D Bauer, J Krege, N Lane, E Leary, C Libanati, P Miller, G Myers, ... Osteoporosis International 23, 2425-2433, 2012 | 180 | 2012 |
| Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX EV McCloskey, H Johansson, A Oden, M Austin, E Siris, A Wang, ... Journal of Bone and Mineral Research 27 (7), 1480-1486, 2012 | 162 | 2012 |
| Differing effects of denosumab and alendronate on cortical and trabecular bone RM Zebaze, C Libanati, M Austin, A Ghasem-Zadeh, DA Hanley, ... Bone 59, 173-179, 2014 | 158 | 2014 |
| One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study EM Lewiecki, RV Dinavahi, M Lazaretti‐Castro, PR Ebeling, JD Adachi, ... Journal of Bone and Mineral Research 34 (3), 419-428, 2019 | 149 | 2019 |
| FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab F Cosman, DB Crittenden, S Ferrari, A Khan, NE Lane, K Lippuner, ... Journal of bone and mineral research 33 (7), 1219-1226, 2018 | 142 | 2018 |
| Biochemical markers of bone turnover for the clinical assessment of bone metabolism AK Taylor, SA Lueken, C Libanati, DJ Baylink Rheumatic Disease Clinics of North America 20 (3), 589-607, 1994 | 141 | 1994 |
